Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018
Рет қаралды 12,333
Күн бұрынCDER’s Maureen Dillon-Parker and Judit Milstein discuss the content and format of an initial IND submission and what to expect during the first 30 days, including processes for clinical holds and best practices.
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming training and free continuing education credits: www.fda.gov/cd...
CDER SBIA 2018 Playlist: • 2018 CDER Small Busine...
LinkedIn: / cder-small-business-an...
Training resources: www.fda.gov/cd...
Twitter: / fda_drug_info
CDER small business e-mail update subscription: updates.fda.go...
Email: CDERSBIA@fda.hhs.gov
Phone: (301) 796-6707 I (866) 405-5367
U.S. Food and Drug Administration
Рет қаралды 12 М.
U.S. Food and Drug Administration
Рет қаралды 28 М.
U.S. Food and Drug Administration
Рет қаралды 5 М.
U.S. Food and Drug Administration
Рет қаралды 4,1 М.
U.S. Food and Drug Administration
Рет қаралды 12 М.
Demystifying the Investigational New Drug (IND) Application for Drugs and Biologics (3of14) REdI '18
U.S. Food and Drug Administration
Рет қаралды 5 М.
U.S. Food and Drug Administration
Рет қаралды 15 М.
In vitro bioequivalence testing for topical ophthalmic suspension products (17of39) Complex Generics
U.S. Food and Drug Administration
Рет қаралды 3,4 М.
U.S. Food and Drug Administration
Рет қаралды 2,7 М.
U.S. Food and Drug Administration
Рет қаралды 6 М.
U.S. Food and Drug Administration
Рет қаралды 20 М.
U.S. Food and Drug Administration
Рет қаралды 2,4 М.